ALK and non-small cell lung carcinoma: Crizotinib has already demonstrated high response rates with minimal toxicity for the treatment of ALK-positive non-small cell lung cancer (NSCLC) and has already been established as standard of care first line therapy in lieu of platinum based chemotherapy [80].